

Summary of Evidence to date for Epsilon Toxin (ETX) in Multiple Sclerosis patients

Evidence	MS Patients	Controls
Prevalence of antibodies to ETX in serum	23% – 35% (N = 125)	8% - 14% (N = 125)
Peptides reactive to ETX using Pepscan Analysis	35% (N = 43)	12% (N = 32)
Prevalence of ETX in CD4S and CD8s	33% (N=36)	16% (N=30?)
Prevalence of B and D Strains of <i>C. perfringens</i> in faecal samples	21% (N=28)	0% (N=20)